C-Peptide (Connecting Peptide)

1. Overview

C-Peptide (Connecting Peptide) is a 31-amino acid polypeptide that constitutes the central segment of proinsulin, connecting the insulin A-chain and B-chain within the proinsulin precursor molecule [1][12]. When proinsulin is proteolytically processed in pancreatic beta-cell secretory granules by the prohormone convertases PC1/3 and PC2, C-peptide is excised and released into the portal circulation in equimolar amounts with mature insulin [1][14]. The human C-peptide sequence is EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ, with a molecular weight of approximately 3,020 Da [20].

For decades after its discovery by Donald Steiner in 1967 as part of the proinsulin structure, C-peptide was regarded as a biologically inert cleavage byproduct whose sole physiological role was facilitating the proper folding and disulfide bond formation of insulin within the endoplasmic reticulum [1]. Its clinical utility was limited to serving as a surrogate marker of endogenous insulin secretion -- a role for which it is ideally suited due to its 1:1 equimolar release with insulin, its lack of hepatic first-pass extraction (unlike insulin, which undergoes approximately 50% hepatic clearance), and its longer half-life of 30-35 minutes compared to 3-5 minutes for insulin [14][19].

This view was fundamentally challenged beginning in the early 1990s by the work of John Wahren, Bo-Lennart Johansson, and their colleagues at the Karolinska Institute in Stockholm, who demonstrated that C-peptide possesses intrinsic biological activity. Their research showed that C-peptide binds specifically to cell membranes via a pertussis toxin-sensitive G-protein coupled receptor, activates Ca2+-dependent intracellular signaling cascades, stimulates Na+/K+-ATPase activity, enhances endothelial nitric oxide synthase (eNOS) expression and activity, improves microvascular blood flow, and ameliorates renal and nerve dysfunction in type 1 diabetes [1][5][6]. These findings suggested that the absence of C-peptide in type 1 diabetes (where beta cells are destroyed) may contribute to the development of microvascular complications beyond what can be attributed to hyperglycemia and insulin deficiency alone.

The therapeutic promise of C-peptide replacement ultimately culminated in Cebix Inc.'s development of Ersatta, a pegylated long-acting C-peptide formulation. However, the definitive Phase IIb trial (2015) failed its primary endpoint, leading to the company's dissolution and casting uncertainty over the therapeutic future of C-peptide [13][17]. Despite this setback, C-peptide remains one of the most important clinical biomarkers in endocrinology, essential for diabetes classification, assessment of residual beta-cell function, and the differential diagnosis of hypoglycemic disorders [14][15][19].

Molecular Weight

~3,020 Da (human C-peptide)

Sequence

EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ (31 amino acids)

Gene

INS gene (chromosome 11p15.5); C-peptide is encoded within the proinsulin precursor

Half-life

~30-35 minutes (vs ~3-5 minutes for insulin)

Putative Receptor

GPR146 (proposed but debated); signals via pertussis toxin-sensitive G-protein, Ca2+, MAPK, PKC

Co-secreted With

Insulin, in 1:1 equimolar ratio from pancreatic beta-cell secretory granules

Routes Studied

Subcutaneous injection, intravenous infusion (research)

Regulatory Status

Not approved as therapeutic; widely used as clinical biomarker

Normal Range (Fasting)

0.8-3.85 ng/mL (0.26-1.27 nmol/L)

2. Molecular Biology and Structure

Proinsulin Processing

C-peptide is encoded within the INS gene on chromosome 11p15.5. The gene product is preproinsulin, a 110-amino acid precursor consisting of a signal peptide (24 residues), the insulin B-chain (30 residues), C-peptide (31 residues flanked by two pairs of basic amino acid residues -- Arg-Arg and Lys-Arg -- that serve as cleavage sites), and the insulin A-chain (21 residues) [1][12].

Within the rough endoplasmic reticulum of pancreatic beta cells, the signal peptide is cleaved co-translationally, yielding proinsulin (86 residues). Proinsulin folds and forms three disulfide bonds: two interchain bonds (A7-B7 and A20-B19) linking the A and B chains, and one intrachain bond (A6-A11) within the A chain. C-peptide is essential during this process, positioning the A and B chains in the correct spatial orientation to enable proper disulfide bond formation [1][12].

Proinsulin is then transported through the Golgi apparatus and packaged into immature secretory granules. Within the maturing granules, the prohormone convertases PC1/3 (also called PC1) and PC2 sequentially cleave C-peptide from proinsulin. PC1/3 cleaves at the C-peptide/B-chain junction (after Arg-Arg), while PC2 cleaves at the A-chain/C-peptide junction (after Lys-Arg). The resulting basic amino acid remnants are trimmed by carboxypeptidase E, yielding mature insulin, free C-peptide, and the basic residues [1]. Equimolar amounts of insulin and C-peptide are stored in the secretory granule crystalline core (along with zinc ions) and are co-released upon glucose-stimulated exocytosis.

Solution Structure

NMR spectroscopy studies have revealed that human C-peptide is largely disordered in aqueous solution, lacking a defined tertiary structure under physiological conditions [20]. However, two regions show some structural organization: the N-terminal region (residues 2-5) forms a type I beta-turn, while the C-terminal region (residues 27-31, the pentapeptide EGSLQ) adopts the most well-defined conformation, including a type III-prime beta-turn [20]. The C-peptide is negatively charged at physiological pH, with five glutamic acid and one aspartic acid residues contributing to its overall negative charge.

The C-terminal pentapeptide has been identified as the minimal active fragment required for several of C-peptide's biological effects, including stimulation of Na+/K+-ATPase activity [1][9]. The middle segment (residues 12-21, rich in glycine and alanine) is the most flexible and disordered portion.

Pharmacokinetics

C-peptide has markedly different pharmacokinetics from insulin, making it a superior marker of beta-cell secretion [14][19]:

• Half-life: 30-35 minutes (vs. 3-5 minutes for insulin)
• Hepatic extraction: Negligible (vs. ~50% first-pass hepatic extraction for insulin)
• Clearance: Primarily renal; C-peptide is filtered by the glomerulus and degraded in proximal tubular cells
• Steady-state levels: Peripheral C-peptide levels are 5-10 times higher than insulin due to longer half-life and lack of hepatic extraction
• Renal impairment: C-peptide levels are elevated in chronic kidney disease due to reduced renal clearance, complicating interpretation in patients with renal failure [19]

3. Mechanism of Action

Receptor Binding and Signal Transduction

C-peptide binds specifically to cell membranes in a saturable, stereoselective manner at nanomolar concentrations [1]. The binding is not displaced by insulin, confirming that C-peptide does not act through the insulin receptor. In 2013, Yosten and colleagues identified GPR146, an orphan G-protein coupled receptor, as a candidate C-peptide receptor based on evidence that GPR146 knockdown blocked C-peptide-induced cFos expression and that C-peptide caused GPR146 internalization in KATOIII cells [2]. However, subsequent independent work by Lim et al. (2020) failed to replicate these findings, detecting no significant intracellular response to C-peptide at concentrations up to 33 micromolar in GPR146-expressing cells [3]. The identity of the C-peptide receptor therefore remains an open question.

Despite the receptor controversy, the downstream signaling pathways activated by C-peptide are well characterized [1][11][21]:

G-protein coupling. C-peptide signaling is sensitive to pertussis toxin, implicating a Gi/Go-type G-protein. Receptor activation triggers opening of Ca2+ channels, increasing intracellular Ca2+ concentration.

MAPK/ERK pathway. C-peptide activates the mitogen-activated protein kinase (MAPK) cascade, including ERK1/2 and JNK phosphorylation, through PKC-dependent mechanisms. This pathway mediates transcriptional upregulation of target genes including eNOS [11].

PLCgamma/PKC axis. Phospholipase C-gamma activation generates inositol trisphosphate (IP3) and diacylglycerol (DAG), the latter activating protein kinase C (PKC).

Na+/K+-ATPase Activation

One of the most consistently demonstrated effects of C-peptide is stimulation of Na+/K+-ATPase activity across multiple cell types including renal tubular cells, erythrocytes, and nerve cells [1][7][9]. The mechanism involves Ca2+-calmodulin activation of protein phosphatase 2B (calcineurin/PP2B), which dephosphorylates the alpha subunit of Na+/K+-ATPase, converting it from its phosphorylated inactive form to its dephosphorylated active form [1]. This effect is abolished by the Na+/K+-ATPase inhibitor ouabain and is dependent on intracellular Ca2+ and PKC [9].

The physiological consequences of Na+/K+-ATPase stimulation include:

• Restoration of Na+ and K+ electrochemical gradients across cell membranes
• Improved nerve conduction velocity in diabetic neuropathy
• Enhanced erythrocyte deformability (via maintenance of cell volume and membrane flexibility)
• Reduced tubular sodium reabsorption in the kidney, contributing to anti-hyperfiltration effects

eNOS Stimulation and Nitric Oxide Production

C-peptide increases nitric oxide (NO) production through two complementary mechanisms [1][11]:

1. Acute activation: Ca2+-calmodulin-dependent direct activation of eNOS, increasing enzymatic activity within minutes
2. Transcriptional upregulation: ERK1/2-dependent phosphorylation of transcription factors that enhance eNOS gene expression, increasing eNOS protein levels over hours [11]

The resulting increase in NO bioavailability mediates vasodilation, anti-inflammatory effects, and anti-thrombotic activity in the microvasculature [8][11].

Anti-inflammatory Effects

C-peptide exerts anti-inflammatory actions by reducing hyperglycemia-induced formation of reactive oxygen species (ROS) and inhibiting nuclear factor-kappaB (NF-kappaB) activation [10]. Downstream consequences include decreased expression of endothelial cell adhesion molecules (VCAM-1, E-selectin), reduced leukocyte rolling and adhesion to the vascular endothelium, diminished transmigration of inflammatory cells, and decreased cytokine and chemokine production [10].

4. Researched Applications

Diabetic Neuropathy (Moderate Evidence)

Diabetic peripheral neuropathy affects up to 50% of patients with type 1 diabetes and is characterized by progressive loss of sensory nerve function, beginning distally. The Wahren group hypothesized that C-peptide deficiency contributes to nerve dysfunction through impaired Na+/K+-ATPase activity and endoneurial blood flow.

In the initial proof-of-concept trial, Ekberg et al. (2003) demonstrated that subcutaneous C-peptide replacement (1.5 mg/day in four divided doses for 3 months) improved sensory nerve conduction velocity (SCV) and vibration perception threshold (VPT) in type 1 diabetes patients with early-stage neuropathy compared to placebo [5]. A subsequent larger multicenter trial (2007) involving 139 patients over 6 months confirmed these findings, with significantly more C-peptide-treated patients showing SCV improvement exceeding 1.0 m/s compared to placebo [4].

However, the definitive Cebix Phase IIb trial (published 2016) dampened enthusiasm. This 52-week, double-blind, placebo-controlled trial randomized 250 type 1 diabetes patients with peripheral neuropathy to receive once-weekly pegylated C-peptide (Ersatta) at 0.8 mg, 2.4 mg, or placebo [13]. The primary endpoint -- sural nerve conduction velocity -- improved by 2.1 to 2.5 m/s across all groups with no statistically significant difference between active treatment and placebo. The substantial placebo response was unexpected. A secondary endpoint, vibration perception threshold, did show a 25% dose-dependent improvement with C-peptide, suggesting some biological activity [13][17].

The discrepancy between earlier positive trials and the Phase IIb failure may reflect differences in drug formulation (native C-peptide given four times daily vs. pegylated long-acting form given weekly), patient population, disease stage, trial duration, or the choice of primary endpoint [17].

Diabetic Nephropathy (Moderate Evidence)

C-peptide has shown consistent renoprotective effects in animal models and small human studies [6][7][16][18]. In the kidneys, C-peptide activates Na+/K+-ATPase in tubular cells, reducing sodium reabsorption and attenuating tubuloglomerular feedback-mediated hyperfiltration. Simultaneously, C-peptide stimulates NO release from efferent arteriolar endothelium, causing efferent arteriole dilation and reducing glomerular capillary pressure [7].

Preclinical studies in streptozotocin-induced diabetic rats demonstrated that C-peptide replacement:

• Reduced glomerular hyperfiltration by 15-20%
• Decreased urinary albumin excretion
• Attenuated mesangial matrix expansion
• Increased glomerular eNOS levels
• Reduced TGF-beta expression and extracellular matrix accumulation [16][18]

In human studies, Johansson et al. (2000) showed that C-peptide replacement in type 1 diabetes patients reduced glomerular filtration rate (indicating correction of hyperfiltration) and decreased microalbuminuria [6]. However, these were small, short-term studies (fewer than 25 subjects, weeks to months duration). A systematic review and meta-analysis concluded that while preclinical evidence is compelling, very limited human evidence exists, with only four small studies comparing C-peptide to control [18].

Microvascular Blood Flow (Moderate Evidence)

Impaired microvascular blood flow is an early and central feature of diabetic complications. C-peptide has been shown to increase microvascular blood flow and enhance capillary recruitment in multiple tissues through NO-dependent vasodilation [8]. The effect is specific to the diabetic state; C-peptide has minimal effects on microvascular function in healthy subjects with intact endogenous C-peptide levels [8].

C-peptide also restores erythrocyte deformability -- the ability of red blood cells to change shape and pass through narrow capillaries -- in type 1 diabetes patients [9]. Diabetic erythrocytes have reduced deformability due to impaired Na+/K+-ATPase activity affecting cell volume regulation and membrane flexibility. Forst et al. (2008) demonstrated that C-peptide and its C-terminal fragments restored erythrocyte deformability to normal levels in an ex vivo assay, with the effect completely abolished by ouabain, confirming the Na+/K+-ATPase-dependent mechanism [9]. Importantly, C-peptide had no effect on erythrocytes from healthy controls, indicating a ceiling effect at physiological C-peptide concentrations.

Anti-inflammatory and Vascular Protection (Preclinical Evidence)

In models of inflammatory vascular dysfunction, C-peptide decreased expression of endothelial cell adhesion molecules, reduced leukocyte-endothelial interactions (rolling, adhesion, transmigration), and attenuated hyperglycemia-induced NF-kappaB signaling and ROS generation [10]. These anti-inflammatory effects may contribute to protection against atherosclerosis and macrovascular disease in addition to microvascular complications. However, clinical translation of these findings remains limited.

5. Clinical Biomarker Applications

Diabetes Classification

C-peptide measurement is the gold standard for assessing residual endogenous insulin secretion and is essential for accurate diabetes classification [14][19]:

• Type 1 diabetes: C-peptide is low or undetectable (fasting values typically below 0.2 nmol/L) due to autoimmune destruction of beta cells. Some residual C-peptide may persist for months to years after diagnosis, and its preservation correlates with better glycemic control and reduced hypoglycemia risk.
• Type 2 diabetes: C-peptide is typically normal or elevated early in disease (reflecting hyperinsulinemia and insulin resistance), declining progressively as beta-cell function deteriorates over years.
• Latent autoimmune diabetes in adults (LADA): Intermediate C-peptide levels that decline over time distinguish LADA from classic type 2 diabetes.
• Monogenic diabetes (MODY): Variable C-peptide depending on subtype; measurement helps differentiate from type 1 diabetes.

A fasting C-peptide below 0.6 ng/mL (0.2 nmol/L) predicts absolute insulin requirement, while values above this threshold suggest potential responsiveness to non-insulin therapies [19].

Hypoglycemia Differential Diagnosis

C-peptide is the cornerstone of the diagnostic evaluation of hypoglycemia with hyperinsulinism [14][15]:

• Insulinoma: Both insulin and C-peptide are elevated (molar insulin-to-C-peptide ratio of 1 or less), reflecting endogenous overproduction from a functioning islet cell tumor.
• Factitious hypoglycemia (exogenous insulin): Insulin levels are high but C-peptide is suppressed or undetectable, because exogenous insulin preparations do not contain C-peptide and the resulting hypoglycemia suppresses endogenous secretion [15]. The insulin-to-C-peptide molar ratio exceeds 1.
• Sulfonylurea-induced hypoglycemia: Both insulin and C-peptide are elevated (mimicking insulinoma), requiring drug screening for differentiation.

This diagnostic paradigm, established by Service et al. in 1977, remains the standard approach and has proven invaluable in clinical endocrinology [15].

Testing Methods

C-peptide can be measured under several conditions [14][19]:

• Fasting: Most commonly used clinically; requires 8-12 hour fast with concurrent glucose measurement
• Random (non-fasting): Acceptable if sampling conditions and glucose level are known
• Glucagon stimulation test (GST): 1.0 mg intravenous glucagon with C-peptide measurement at 6 minutes; the most widely used provocative test for residual beta-cell function
• Mixed-meal tolerance test (MMTT): Standardized liquid meal (e.g., Boost) with serial C-peptide measurements; considered the gold standard for research purposes

Modern ultrasensitive C-peptide assays can detect values as low as 0.0015-0.0025 nmol/L, enabling detection of minimal residual secretion previously considered absent [19].

Important limitation: C-peptide levels are elevated in chronic kidney disease due to reduced renal clearance, and measurement is not recommended for diabetes classification in end-stage renal disease [19].

6. Clinical Evidence Summary

7. Dosing in Research

All C-peptide dosing protocols are investigational; no approved therapeutic formulation exists. Research doses have been designed to achieve physiological replacement levels (approximately 1.0-1.5 nmol/L in plasma) in C-peptide-deficient type 1 diabetes patients [1][4][5][6].

Native (unmodified) C-peptide requires multiple daily injections or continuous infusion due to its 30-35 minute half-life. Cebix developed pegylated C-peptide (Ersatta) to enable once-weekly dosing, but this formulation was discontinued after the Phase IIb trial failure [13].

8. Safety and Side Effects

Therapeutic Administration

C-peptide has demonstrated a favorable safety profile in clinical trials at physiological replacement doses [4][5][6][12][13]:

• No serious adverse events attributable to C-peptide were reported in the Wahren/Ekberg trials at doses of 1.5 to 4.5 mg/day for up to 6 months.
• In the Cebix Phase IIb trial, pegylated C-peptide at 0.8 mg and 2.4 mg weekly for 52 weeks showed no significant safety signals compared to placebo [13].
• No hypoglycemia risk, as C-peptide does not directly affect glucose metabolism through insulin receptor activation.
• No immunogenicity concerns reported with native human C-peptide.
• Injection site reactions were minimal and comparable to placebo.

Supraphysiological Considerations

C-peptide at concentrations exceeding physiological levels (above 3-5 nmol/L) does not appear to produce additional biological effects, suggesting a saturable mechanism consistent with receptor-mediated activity [1]. There is no evidence of adverse effects from the elevated C-peptide levels seen in insulin resistance or type 2 diabetes.

Biomarker Safety

C-peptide testing (blood draw) carries only standard venipuncture risks. The glucagon stimulation test may cause transient nausea and rarely vomiting. No serious adverse events have been associated with diagnostic C-peptide measurement protocols [14].

9. The Cebix Story: Rise and Fall of C-Peptide Therapeutics

The trajectory of C-peptide from biomarker to potential therapeutic and back represents one of the most instructive episodes in peptide drug development [12][13][17].

Promise (1990s-2012). Beginning with the Wahren laboratory's discovery of C-peptide's biological activity, over two decades of research accumulated showing benefits in animal models and small human studies across neuropathy, nephropathy, and microvascular dysfunction [1][5][6]. Cebix Inc., a San Diego biotechnology company, licensed the intellectual property and raised over $31 million to develop Ersatta, a pegylated long-acting C-peptide formulation designed for once-weekly injection, with the goal of treating diabetic complications in type 1 diabetes.

Phase IIb trial (2012-2015). The pivotal trial enrolled 250 type 1 diabetes patients with peripheral neuropathy across multiple centers. Patients received Ersatta 0.8 mg weekly, 2.4 mg weekly, or placebo for 52 weeks, with sural nerve conduction velocity (SNCV) as the primary endpoint [13].

Failure and closure (2015). All three groups -- including placebo -- showed SNCV improvement of 2.1 to 2.5 m/s, with no statistically significant difference between active treatment and placebo. As Cebix CEO Joel Martin stated, the results of Ersatta and placebo were "indistinguishable." The company quietly shut down operations in 2015 [13][17].

Lessons and unresolved questions. Shaw et al. (2018) analyzed the failure and identified several possible explanations: (1) the pegylated formulation may have altered C-peptide's pharmacodynamic profile; (2) once-weekly dosing may not replicate the pulsatile, meal-associated C-peptide release that occurs physiologically; (3) the large placebo response in SNCV may have masked a real treatment effect; (4) advanced neuropathy may be irreversible regardless of intervention; (5) the positive secondary endpoint (vibration perception threshold) suggests the concept may retain some validity [17]. The field remains in what Shaw termed "the trough of disillusionment" -- uncertain whether to abandon the therapeutic concept or redesign the approach.

10. Pharmacokinetics

C-peptide pharmacokinetics are well characterized due to its extensive use as a clinical biomarker, providing some of the most detailed PK data available for any endogenous peptide [1][14][19].

Plasma half-life. C-peptide has a plasma half-life of approximately 30-35 minutes, roughly 6-10 times longer than insulin (3-5 minutes) [14][19]. This longer half-life is attributable to two factors: (1) C-peptide does not undergo significant hepatic first-pass extraction (unlike insulin, which has approximately 50% hepatic clearance), and (2) C-peptide is a single-chain, relatively protease-resistant peptide with no exposed disulfide bonds, providing greater stability in circulation than insulin.

Equimolar secretion with insulin. C-peptide is co-secreted with insulin in a strict 1:1 equimolar ratio from pancreatic beta-cell secretory granules [1][14]. Each molecule of proinsulin yields exactly one molecule of insulin and one molecule of C-peptide. This stoichiometric relationship, combined with C-peptide's more predictable clearance kinetics, makes C-peptide the superior marker of endogenous insulin secretion.

Renal clearance. C-peptide is cleared primarily by the kidneys through glomerular filtration followed by degradation in proximal tubular cells [14][19]. Renal clearance of C-peptide is approximately 4-5 mL/min. This renal-predominant clearance has an important clinical implication: C-peptide levels are elevated in patients with chronic kidney disease due to reduced renal clearance, complicating interpretation of C-peptide as a beta-cell function marker in patients with renal impairment [19].

Steady-state levels. Due to its longer half-life and lack of hepatic extraction, peripheral C-peptide concentrations are 5-10 times higher than peripheral insulin concentrations at steady state [14]. Normal fasting C-peptide ranges from 0.8 to 3.85 ng/mL (0.26-1.27 nmol/L), while stimulated levels (post-meal or post-glucagon) can reach 3-10 ng/mL [14][19].

Pharmacokinetics of therapeutic C-peptide. In the Wahren/Ekberg clinical studies, subcutaneous C-peptide replacement was administered as 1.5 mg/day divided into four doses (approximately 0.375 mg per dose every 6 hours) to achieve physiological replacement levels of approximately 1.0-1.5 nmol/L in plasma [4][5]. The 30-35 minute half-life necessitates multiple daily injections for sustained physiological replacement, which was a major practical limitation for chronic therapy.

Pegylated C-peptide (Ersatta) pharmacokinetics. Cebix developed pegylated C-peptide (Ersatta) by conjugating polyethylene glycol to native C-peptide, extending the half-life sufficiently to allow once-weekly subcutaneous injection [13]. The pegylated form achieved sustained plasma C-peptide levels over the 7-day dosing interval. Doses of 0.8 mg and 2.4 mg weekly were tested in the Phase IIb trial [13]. Whether the continuous (non-pulsatile) exposure from the pegylated form adequately reproduces the biological effects of the physiologically pulsatile C-peptide secretion that occurs with meals remains an unresolved pharmacokinetic question [17].

Distribution. C-peptide distributes broadly to vascular endothelium, renal tubular cells, peripheral nerves, and erythrocytes -- the tissues where its biological effects have been documented [1][8][9]. The volume of distribution is consistent with extracellular distribution, typical of a hydrophilic polypeptide.

11. Dose-Response Relationships

C-peptide dose-response relationships have been characterized in both physiological and pharmacological contexts [1][4][5][6][13].

Physiological concentration-response. C-peptide's biological effects (Na+/K+-ATPase stimulation, eNOS activation, anti-inflammatory activity) occur at nanomolar concentrations corresponding to the physiological range (0.5-2.0 nmol/L) [1]. At supraphysiological concentrations (above 3-5 nmol/L), C-peptide does not appear to produce additional biological effects, suggesting a saturable, receptor-mediated mechanism with a ceiling effect [1]. This saturation explains why elevated C-peptide levels in type 2 diabetes (often 2-5 fold above normal) do not produce excessive biological activation -- the system is already maximally stimulated at physiological concentrations.

Neuropathy dose-response. In the Ekberg et al. (2007) multicenter trial, two dose levels were tested: 1.5 mg/day and 4.5 mg/day subcutaneously in divided doses for 6 months [4]. Both doses improved sensory nerve conduction velocity compared to placebo, with significantly more patients showing improvement exceeding 1.0 m/s in the C-peptide groups. The 4.5 mg/day dose did not produce clearly superior efficacy over the 1.5 mg/day dose, consistent with the ceiling effect observed in vitro at supraphysiological concentrations [4].

Renal dose-response. C-peptide replacement at physiological doses (6 pmol/kg/min IV infusion achieving plasma levels of approximately 1.0-1.5 nmol/L) reduced glomerular hyperfiltration and microalbuminuria in type 1 diabetes patients [6][7]. These effects were observed at replacement doses restoring C-peptide to the normal range rather than at pharmacological doses, suggesting that the therapeutic benefit derives from correcting a deficiency state rather than producing a supraphysiological drug effect.

Pegylated C-peptide dose-response (Phase IIb). The Cebix trial tested two doses of weekly pegylated C-peptide: 0.8 mg and 2.4 mg [13]. Neither dose achieved statistical separation from placebo on the primary endpoint (sural nerve conduction velocity), though the secondary endpoint of vibration perception threshold showed a 25% dose-dependent improvement, suggesting that the dose-response for this particular outcome was preserved even when the primary outcome failed [13].

Erythrocyte deformability dose-response. Forst et al. (2008) demonstrated that C-peptide restoration of erythrocyte deformability follows a concentration-dependent curve up to physiological levels, with no additional effect above approximately 1.5-2.0 nmol/L [9]. This was confirmed by the observation that C-peptide had no effect on erythrocytes from healthy controls (who already have physiological C-peptide levels), demonstrating the ceiling effect in vivo.

C-terminal pentapeptide dose-response. The C-terminal pentapeptide (EGSLQ, residues 27-31) has been identified as the minimal active fragment for Na+/K+-ATPase stimulation [1][9]. This fragment retains biological activity at concentrations similar to the full-length C-peptide, suggesting that the C-terminal region contains the receptor-binding pharmacophore.

12. Comparative Effectiveness

C-Peptide vs. Alpha-Lipoic Acid for Diabetic Neuropathy

Alpha-lipoic acid (ALA) is the most extensively studied antioxidant treatment for diabetic neuropathy and is approved in several European countries for this indication. The SYDNEY, SYDNEY 2, and NATHAN-1 trials demonstrated that IV ALA (600 mg daily for 3 weeks) and oral ALA (600 mg daily for up to 4 years) improve neuropathic symptoms and nerve conduction parameters in type 2 diabetes patients. C-peptide and ALA operate through fundamentally different mechanisms: C-peptide restores Na+/K+-ATPase activity and endoneurial blood flow (addressing deficiency-specific pathophysiology in type 1 diabetes), while ALA scavenges free radicals and regenerates other antioxidants (addressing oxidative stress that occurs in both type 1 and type 2 diabetes). Critically, C-peptide replacement is specific to type 1 diabetes where C-peptide is deficient, while ALA is applicable to neuropathy in both type 1 and type 2 diabetes. The positive early C-peptide trials (Ekberg 2003, 2007) showed improvements comparable in magnitude to ALA studies, but the Phase IIb Ersatta trial failure raises questions about whether C-peptide's effects are robust enough to meet stringent endpoints [4][5][13].

C-Peptide vs. Standard of Care for Diabetic Neuropathy

No FDA-approved disease-modifying treatment for diabetic neuropathy exists. Current management consists of glycemic optimization (which slows progression but does not reverse established neuropathy in type 1 diabetes) and symptomatic pain management (pregabalin, duloxetine, gabapentin). C-peptide replacement addresses a pathophysiologically distinct mechanism (Na+/K+-ATPase deficiency) that is not targeted by any existing therapy, making it a unique potential addition rather than a replacement for current management. However, the Cebix Phase IIb failure means that the clinical utility of C-peptide replacement for neuropathy remains unproven.

C-Peptide vs. Aldose Reductase Inhibitors

Aldose reductase inhibitors (epalrestat, tolrestat, sorbinil) target the polyol pathway and have been studied for diabetic neuropathy for decades. Epalrestat is approved in Japan and India for diabetic neuropathy. In clinical trials, aldose reductase inhibitors produce modest improvements in nerve conduction velocity (approximately 1-2 m/s) over 1-3 years, comparable to the improvements seen in early C-peptide studies. Like C-peptide, aldose reductase inhibitors target a specific pathological mechanism rather than symptoms. The Cebix trial paradoxically showed improvements of 2.1-2.5 m/s across all groups (including placebo), a magnitude comparable to or exceeding results from aldose reductase inhibitor trials.

| Feature | C-Peptide | Alpha-Lipoic Acid | Pregabalin/Duloxetine | |---|---|---|---| | Mechanism | Na+/K+-ATPase, eNOS, anti-inflammatory | Antioxidant, free radical scavenging | Symptomatic pain relief | | Applicable diabetes type | Type 1 specifically | Type 1 and type 2 | Type 1 and type 2 | | Disease-modifying | Potentially | Potentially | No | | NCV improvement | Yes (early trials), No (Phase IIb) | Yes (NATHAN-1) | No | | Regulatory approval | None | EU (several countries) | FDA-approved (pain) | | Route | SC injection (multiple daily) | Oral or IV | Oral | | Safety profile | Excellent | Good (GI, skin rash) | Sedation, weight gain |

13. Enhanced Safety Profile

C-peptide has one of the most favorable safety profiles of any therapeutic peptide candidate, reflecting its nature as an endogenous human molecule present in all insulin-secreting individuals throughout life [1][4][5][12][13].

Endogenous safety credentials. C-peptide circulates at nanomolar concentrations in all healthy humans and in type 2 diabetes patients, with no adverse effects attributed to these physiological or elevated levels [1][14]. This provides the strongest possible safety foundation: the molecule has been present in the human body for evolutionary timescales without identified toxicity.

No hypoglycemia risk. Unlike insulin and insulin secretagogues, C-peptide does not directly affect glucose metabolism through insulin receptor activation [1]. Therapeutic C-peptide replacement cannot cause hypoglycemia, eliminating the most dangerous side effect of diabetes treatment. This safety advantage is absolute and mechanistically guaranteed.

Clinical trial safety data. Across all published C-peptide trials (Wahren/Ekberg studies: 1.5-4.5 mg/day for up to 6 months; Cebix Phase IIb: 0.8-2.4 mg weekly for 52 weeks), no serious adverse events attributable to C-peptide were reported [4][5][13]. Injection site reactions were minimal and comparable to placebo. No immunogenicity concerns were identified with native human C-peptide. The 52-week Cebix dataset (250 patients) provides the longest-duration safety data, confirming tolerability over 1 year of chronic administration [13].

Saturation pharmacology as safety mechanism. C-peptide's effects plateau at physiological concentrations (approximately 1.5-2.0 nmol/L), and supraphysiological levels do not produce additional activation [1]. This built-in ceiling effect limits the risk of overdose toxicity. Even substantial dose excursions would not be expected to produce harmful levels of Na+/K+-ATPase activation or NO production.

No effect in C-peptide-sufficient individuals. A consistent finding across C-peptide studies is that the peptide has minimal to no effect in healthy subjects or type 2 diabetes patients who already have physiological or elevated C-peptide levels [8][9]. This specificity for the deficiency state (type 1 diabetes) provides additional safety assurance: inadvertent exposure in C-peptide-sufficient individuals would not produce unwanted biological effects.

Type 2 diabetes considerations. Some early concerns were raised about whether C-peptide could promote atherogenesis through VSMC proliferation in the context of the hyperinsulinemia and elevated C-peptide levels seen in type 2 diabetes [10]. However, the concentration-response ceiling effect and the observation that C-peptide does not produce effects above physiological levels largely mitigate this concern [1]. Epidemiological data linking elevated C-peptide to cardiovascular risk in type 2 diabetes likely reflect confounding by insulin resistance rather than direct C-peptide toxicity.

Pegylated formulation considerations. The pegylated C-peptide (Ersatta) formulation introduces additional safety considerations: potential immunogenicity from the PEG moiety, altered biodistribution, and the theoretical concern that continuous non-pulsatile exposure may differ from physiological pulsatile secretion [13][17]. These formulation-specific issues are distinct from the safety of native C-peptide itself.

14. Regulatory Status

C-peptide has no approved therapeutic indication in any major regulatory jurisdiction. It is widely available as a laboratory diagnostic test, measured by immunoassay (chemiluminescence, ELISA, or radioimmunoassay) from all major clinical laboratory platforms [14][19].

Research-grade synthetic human C-peptide is available from multiple peptide suppliers for investigational use. No active clinical trials of C-peptide replacement therapy are currently registered, though academic interest in C-peptide biology continues.

C-Peptide as Validated Surrogate Endpoint (2024-2025)

A major development in the C-peptide field has been its formal validation as a surrogate endpoint for clinical outcomes in type 1 diabetes disease-modifying trials. An individual participant meta-analysis published in The Lancet Diabetes and Endocrinology (2024) demonstrated that C-peptide preservation in trials of immunomodulatory therapies (such as teplizumab, rituximab, and abatacept) directly predicts long-term metabolic and clinical benefits, including reduced HbA1c, lower insulin requirements, and decreased hypoglycemia risk. Separately, a 2024 analysis in Diabetes confirmed that C-peptide meets criteria as a validated surrogate endpoint for predicting clinical benefits in disease-modifying therapy trials for new-onset type 1 diabetes, strengthening its role in regulatory submissions for therapies aimed at preserving beta-cell function.

In 2025-2026, a comprehensive review published in precision diabetes care highlighted the expanding role of C-peptide measurement beyond traditional diabetes classification into prognostic modeling for type 1 diabetes progression, monitoring of beta-cell preservation therapies, and individualized treatment decision-making. C-peptide is now incorporated into models predicting progression from Stage 2 to Stage 3 type 1 diabetes, and ultra-sensitive assays (detection limit 0.0015-0.0025 nmol/L) are enabling identification of minimal residual beta-cell function previously considered absent.

15. Related Peptides

See also: Insulin, Amylin (IAPP), GLP-1, Pramlintide (Symlin)

16. References

1. [1] Wahren J, Ekberg K, Johansson J, et al. (2000). Role of C-peptide in human physiology. American Journal of Physiology - Endocrinology and Metabolism. DOI PubMed
2. [2] Yosten GLC, Kolar GR, Redlinger LJ, et al. (2013). Evidence for an interaction between proinsulin C-peptide and GPR146. Journal of Endocrinology. DOI PubMed
3. [3] Lim YC, Bhatt MP, Kwon MH, et al. (2020). Is GPR146 really the receptor for proinsulin C-peptide?. Bioorganic and Medicinal Chemistry Letters. DOI PubMed
4. [4] Ekberg K, Brismar T, Johansson BL, et al. (2007). C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care. DOI PubMed
5. [5] Ekberg K, Brismar T, Johansson BL, et al. (2003). Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes. Diabetes. DOI PubMed
6. [6] Johansson BL, Borg K, Fernqvist-Forbes E, et al. (2000). Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabetic Medicine. DOI PubMed
7. [7] Sjoquist M, Huang W, Johansson BL. (1998). Effects of C-peptide on renal function at the early stage of experimental diabetes. Kidney International. DOI PubMed
8. [8] Haidet J, Cifarelli V, Bhatt N, et al. (2009). Role of C-Peptide in the regulation of microvascular blood flow. Experimental Diabetes Research. DOI PubMed
9. [9] Forst T, De La Tour DD, Kunt T, et al. (2008). C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients. Experimental Diabetes Research. DOI PubMed
10. [10] Walcher D, Babiak C, Polber P, et al. (2004). C-peptide induces vascular smooth muscle cell proliferation through mitogen-activated protein kinase-dependent pathway. Arteriosclerosis, Thrombosis, and Vascular Biology. DOI PubMed
11. [11] Luppi P, Cifarelli V, Tse H, et al. (2003). Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells. Diabetologia. DOI PubMed
12. [12] Wahren J, Kallas A, Sima AAF. (2012). The clinical potential of C-peptide replacement in type 1 diabetes. Diabetes. DOI PubMed
13. [13] Kallas A, Bhatt NM, Engel S, et al. (2016). Long-acting C-peptide and neuropathy in type 1 diabetes - a 12-month clinical trial. Diabetes Care. DOI PubMed
14. [14] Jones AG, Hattersley AT. (2013). The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine. DOI PubMed
15. [15] Service FJ, Dale AJ, Elveback LR, et al. (1977). Factitious hypoglycemia: diagnosis by measurement of serum C-peptide immunoreactivity and insulin-binding antibodies. New England Journal of Medicine. DOI PubMed
16. [16] Hills CE, Brunskill NJ. (2009). C-Peptide: the missing link in diabetic nephropathy?. Experimental Diabetes Research. DOI PubMed
17. [17] Shaw JA, Sherwood W, Sherwood D. (2018). C-Peptide replacement therapy in type 1 diabetes: are we in the trough of disillusionment?. Diabetic Medicine. DOI PubMed
18. [18] Brunskill NJ. (2017). C-peptide and diabetic kidney disease. Journal of Internal Medicine. DOI PubMed
19. [19] Leighton E, Sainsbury CA, Jones GC. (2017). A practical review of C-peptide testing in diabetes. Diabetes Therapy. DOI PubMed
20. [20] Munte CE, Vilela L, Kalbitzer HR, et al. (2005). Solution structure of human proinsulin C-peptide. FEBS Journal. DOI PubMed
21. [21] Zhong Z, Davidescu A, Bhatt NM, et al. (2014). Physiological effects and therapeutic potential of proinsulin C-peptide. American Journal of Physiology - Endocrinology and Metabolism. DOI PubMed